{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:22:00Z","timestamp":1740108120743,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurg"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Therapie des Lungenkarzinoms wurde in den letzten Jahren zunehmend durch die Etablierung tumorspezifisch zielgerichteter Pharmaka und immunmodulatorischer Ans\u00e4tze erg\u00e4nzt und hat dadurch rasant an Komplexit\u00e4t gewonnen. Bessere \u00dcberlebensdaten und Erkenntnisse \u00fcber andere Nebenwirkungensspektren und Rezidivcharakteristika begleiten diese Entwicklung. Dem Kliniker verlangt diese Entwicklung eine stete Wachsamkeit in der Stratifizierung der Behandlungsoptionen ab. Dieser Artikel gibt einen \u00dcberblick \u00fcber die klinisch aktuell relevanten Ans\u00e4tze der \u201etargeted therapies\u201c in der Behandlung des Lungenkarzinoms und stellt Verbindungen zur Thoraxchirurgie dar. Mit der Darstellung der Optionen einer zielgerichteter Therapie wird beantwortet, welche Rolle sie in der adjuvanten Therapie bei nachgewiesener Mutation des Epidermal-growth-factor-Rezeptors (<jats:italic>EGFR<\/jats:italic>) spielen, wann eine Salvage-Operation infrage kommt und wie durch die \u201etargeted therapies\u201c in Einzelf\u00e4llen ein kuratives Therapiekonzept erarbeitet werden kann. Jedes Lungenkarzinom verlangt ab dem fr\u00fchestm\u00f6glichen Zeitpunkt in der Diagnosefindung nach einer molekularen Analyse auf therapierelevante Mutationsmuster. Interdisziplin\u00e4re Konzepte k\u00f6nnen individualisiert das Langzeit\u00fcberleben des Patienten gew\u00e4hrleisten.<\/jats:p>","DOI":"10.1007\/s00104-021-01544-0","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T12:16:54Z","timestamp":1639484214000},"page":"485-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molekularpathologie in der Behandlung des Lungenkarzinoms\u00a0\u2013 interdisziplin\u00e4rer Blick auf die thoraxchirurgische Bedeutung","Molecule pathology in the treatment of lung cancer\u2014Interdisciplinary view of the importance in thoracic surgery"],"prefix":"10.1007","volume":"93","author":[{"given":"Sebastian","family":"Kr\u00e4mer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"1544_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/CCO.0000000000000429","volume":"30","author":"F Oberndorfer","year":"2018","unstructured":"Oberndorfer\u00a0F, M\u00fcllauer\u00a0L (2018) Molecular pathology of lung cancer: current status and perspectives. Curr Opin Oncol 30:69\u201376. https:\/\/doi.org\/10.1097\/CCO.0000000000000429","journal-title":"Curr Opin Oncol"},{"key":"1544_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader\u00a0N, Forjaz\u00a0G, Mooradian\u00a0MJ et al (2020) The effect of advances in lung-cancer treatment on population mortality. N\u00a0Engl J Med 383:640\u2013649. https:\/\/doi.org\/10.1056\/NEJMoa1916623","journal-title":"N Engl J Med"},{"key":"1544_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","volume":"6","author":"WD Travis","year":"2011","unstructured":"Travis\u00a0WD, Brambilla\u00a0E, Noguchi\u00a0M et\u00a0al (2011) International association for the study of lung cancer\/american thoracic society\/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J\u00a0Thorac Oncol 6:244\u2013285. https:\/\/doi.org\/10.1097\/JTO.0b013e318206a221","journal-title":"J Thorac Oncol"},{"key":"1544_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"The Cancer Genome Atlas Research Network","year":"2014","unstructured":"The Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543\u2013550. https:\/\/doi.org\/10.1038\/nature13385","journal-title":"Nature"},{"key":"1544_CR5","unstructured":"(2018) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Leitlinienreport 1.0, 2018, AWMF Registernummer 020\/007 OL. http:\/\/leitlinienprogrammonkologie.de\/Lungenkarzinom.98.0.html. Zugegriffen: Mai 2021"},{"key":"1544_CR6","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele\u00a0F, Remon\u00a0J, Mateo\u00a0J et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a\u00a0report from the ESMO Precision Medicine Working Group. Ann Oncol 31:1491\u20131505. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.014","journal-title":"Ann Oncol"},{"key":"1544_CR7","unstructured":"Griesinger F, Eberhardt W, Fr\u00fch M, Gautschi O, Hilbe W, Hoffmann H, Huber RM, Loges S, Pirker R, P\u00f6ttgen C, Pritzkuleit R, Reck M, Reinmuth N, Sebastian M, Ukena D, Waller C, Wolf J, Wolf M, W\u00f6rmann B (2019) onkopedia Leitlinie: Lungenkarzinom, nicht-kleinzellig (NSCLC). https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/lungenkarzinom-nicht-kleinzellig-nsclc\/@@guideline\/html\/index.html#ID0EDMAG. Zugegriffen: Mai 2021"},{"key":"1544_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fonc.2017.00050","volume":"7","author":"SV Soldera","year":"2017","unstructured":"Soldera\u00a0SV, Leighl\u00a0NB (2017) Update on the treatment of metastatic squamous non-small cell lung cancer in new era of personalized medicine. Front Oncol 7:50. https:\/\/doi.org\/10.3389\/fonc.2017.00050","journal-title":"Front Oncol"},{"key":"1544_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jtho.2016.01.012","volume":"11","author":"PA Bunn","year":"2016","unstructured":"Bunn\u00a0PA, Minna\u00a0JD, Augustyn\u00a0A et\u00a0al (2016) Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? J\u00a0Thorac Oncol 11:453\u2013474. https:\/\/doi.org\/10.1016\/j.jtho.2016.01.012","journal-title":"J Thorac Oncol"},{"key":"1544_CR10","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","volume":"24","author":"S Dearden","year":"2013","unstructured":"Dearden\u00a0S, Stevens\u00a0J, Wu\u00a0Y\u2011L et al (2013) Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 24:2371\u20132376. https:\/\/doi.org\/10.1093\/annonc\/mdt205","journal-title":"Ann Oncol"},{"key":"1544_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma\u00a0SV, Bell\u00a0DW, Settleman\u00a0J et\u00a0al (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169\u2013181. https:\/\/doi.org\/10.1038\/nrc2088","journal-title":"Nat Rev Cancer"},{"key":"1544_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010383.pub2","author":"J Greenhalgh","year":"2016","unstructured":"Greenhalgh\u00a0J, Dwan\u00a0K, Boland\u00a0A et al (2016) First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD010383.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1544_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cca.2013.11.014","volume":"429","author":"A Vall\u00e9e","year":"2014","unstructured":"Vall\u00e9e\u00a0A, Le Loupp\u00a0A\u2011G, Denis\u00a0MG (2014) Efficiency of the Therascreen\u00ae RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas. Clin Chim Acta 429:8\u201311. https:\/\/doi.org\/10.1016\/j.cca.2013.11.014","journal-title":"Clin Chim Acta"},{"key":"1544_CR14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1634\/theoncologist.2016-0458","volume":"22","author":"CS Baik","year":"2017","unstructured":"Baik\u00a0CS, Myall\u00a0NJ, Wakelee\u00a0HA (2017) Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy. Oncologist 22:786\u2013796. https:\/\/doi.org\/10.1634\/theoncologist.2016-0458","journal-title":"Oncologist"},{"key":"1544_CR15","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard\u00a0D, Besse\u00a0B, Groen\u00a0HJM et al (2016) Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17:984\u2013993. https:\/\/doi.org\/10.1016\/S1470-2045(16)30146-2","journal-title":"Lancet Oncol"},{"key":"1544_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9080107","author":"P Hofman","year":"2017","unstructured":"Hofman\u00a0P (2017) ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a\u00a0daily practice. Cancers. https:\/\/doi.org\/10.3390\/cancers9080107","journal-title":"Cancers"},{"key":"1544_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nrclinonc.2014.180","volume":"11","author":"D Killock","year":"2014","unstructured":"Killock\u00a0D (2014) Lung cancer: alternative rearrangements\u2014targeting ROS1 in NSCLC. Nat Rev Clin Oncol 11:624. https:\/\/doi.org\/10.1038\/nrclinonc.2014.180","journal-title":"Nat Rev Clin Oncol"},{"key":"1544_CR18","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.jtcvs.2017.06.062","volume":"154","author":"K Takamochi","year":"2017","unstructured":"Takamochi\u00a0K, Oh\u00a0S, Matsunaga\u00a0T et\u00a0al (2017) Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma. J\u00a0Thorac Cardiovasc Surg 154:1768\u20131774.e1. https:\/\/doi.org\/10.1016\/j.jtcvs.2017.06.062","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1544_CR19","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"Y-L Wu","year":"2020","unstructured":"Wu\u00a0Y\u2011L, Tsuboi\u00a0M, He\u00a0J et al (2020) Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N\u00a0Engl J Med 383:1711\u20131723. https:\/\/doi.org\/10.1056\/NEJMoa2027071","journal-title":"N Engl J Med"},{"key":"1544_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123881","author":"S Suzuki","year":"2020","unstructured":"Suzuki\u00a0S, Goto\u00a0T (2020) Role of surgical intervention in unresectable non-small cell lung cancer. J\u00a0Clin Med. https:\/\/doi.org\/10.3390\/jcm9123881","journal-title":"J Clin Med"},{"key":"1544_CR21","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/j.jtcvs.2010.06.035","volume":"140","author":"T Hishida","year":"2010","unstructured":"Hishida\u00a0T, Nagai\u00a0K, Mitsudomi\u00a0T et al (2010) Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. J\u00a0Thorac Cardiovasc Surg 140:e69\u2013e71. https:\/\/doi.org\/10.1016\/j.jtcvs.2010.06.035","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1544_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11748-014-0508-5","volume":"64","author":"T Hishida","year":"2016","unstructured":"Hishida\u00a0T, Yoshida\u00a0J, Aokage\u00a0K et al (2016) Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases. Gen Thorac Cardiovasc Surg 64:429\u2013433. https:\/\/doi.org\/10.1007\/s11748-014-0508-5","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"1544_CR23","doi-asserted-by":"publisher","first-page":"e00451","DOI":"10.1002\/rcr2.451","volume":"7","author":"Y Horio","year":"2019","unstructured":"Horio\u00a0Y, Mizuno\u00a0T, Sakao\u00a0Y et al (2019) Successful salvage surgery following multimodal therapy in a\u00a0patient who harboured ALK-rearranged advanced lung adenocarcinoma with multiple organ metastases. Respirol Case Rep 7:e451. https:\/\/doi.org\/10.1002\/rcr2.451","journal-title":"Respirol Case Rep"}],"container-title":["Der Chirurg"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-021-01544-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-021-01544-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-021-01544-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T15:10:21Z","timestamp":1650985821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-021-01544-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1007\/s00104-021-01544-0","relation":{},"ISSN":["0009-4722","1433-0385"],"issn-type":[{"type":"print","value":"0009-4722"},{"type":"electronic","value":"1433-0385"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"assertion":[{"value":"8 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Kr\u00e4mer und H.\u00a0Wirtz geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}